BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Xu YH, Zhu WM, Guo Z. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol 2022; 28(48): 6888-6899 [PMID: 36632311 DOI: 10.3748/wjg.v28.i48.6888]
URL: https://www.wjgnet.com/1007-9327/full/v28/i48/6888.htm
Number Citing Articles
1
Małgorzata Godala, Ewelina Gaszyńska, Konrad Walczak, Ewa Małecka-Wojciesko. Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel DiseaseJournal of Clinical Medicine 2023; 12(18): 5956 doi: 10.3390/jcm12185956
2
Mohamed Tausif Siddiqui, Rhytha Kasiraj, Maliha Naseer. Medical Management of Ulcerative Colitis and Crohn’s Disease—Strategies for Inducing and Maintaining RemissionSurgical Clinics of North America 2025; 105(2): 435 doi: 10.1016/j.suc.2024.10.007
3
Mikołaj Bugajewski, Norbert Angerhoefer, Leszek Pączek, Beata Kaleta. Lentinula edodes as a Source of Bioactive Compounds with Therapeutical Potential in Intestinal Inflammation and Colorectal CancerInternational Journal of Molecular Sciences 2025; 26(7): 3320 doi: 10.3390/ijms26073320
4
Daopo Lin, Yang Jin, Xiaoxiao Shao, Yuan Xu, Guolong Ma, Yi Jiang, Yinghe Xu, Yongpo Jiang, Dingyuan Hu. Global, regional, and national burden of inflammatory bowel disease, 1990–2021: Insights from the global burden of disease 2021International Journal of Colorectal Disease 2024; 39(1) doi: 10.1007/s00384-024-04711-x
5
Chao Nie, Yunyi Zhao, Pengjie Wang, Ran Wang, Yixuan Li, Xifan Wang, Bing Fang, Xiaoyu Wang, Jing Zhan, Longjiao Zhu, Chong Chen, Weibo Zhang, Haiping Liao, Rong Liu. Momordica charantia Polysaccharide intervention ameliorates the symptoms of dextran sulfate sodium (DSS)-induced colitis by modulating gut microbiota and inhibiting inflammationJournal of Functional Foods 2024; 112: 105970 doi: 10.1016/j.jff.2023.105970
6
Ahmed Aljabri, Ghareb M. Soliman, Yasmin N. Ramadan, Mohammed A. Medhat, Helal F. Hetta. Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systemsClinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01558-6
7
J. Ben Shimol. Perimenopause in women with rheumatologic diseases: a spotlight on an under-addressed transitionClimacteric 2024; 27(2): 115 doi: 10.1080/13697137.2023.2276201
8
Tao Xie, Gao-Yao Cao, Shize Zhang, Meng-Ke Li, Xin Jin, Liu Liu, Guangji Wang, Le Zhen. Discovery of Thiazole Carboxamides as Novel Vanin-1 Inhibitors for Inflammatory Bowel Disease TreatmentJournal of Medicinal Chemistry 2024; 67(22): 20372 doi: 10.1021/acs.jmedchem.4c01838
9
Annalisa Di Rienzo, Lisa Marinelli, Marilisa Pia Dimmito, Eleonora Chiara Toto, Antonio Di Stefano, Ivana Cacciatore. Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery SystemsPharmaceutics 2024; 16(9): 1185 doi: 10.3390/pharmaceutics16091185
10
Inmaculada Serrano, Ana Luque, Alexandra Ruiz-Cerulla, Sergio Navas, Anna M. Blom, Santiago Rodríguez de Córdoba, Francisco J. Fernández, M. Cristina Vega, Francisco Rodríguez-Moranta, Jordi Guardiola, Josep M. Aran. C4BP(β-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patientsPharmacological Research 2023; 197: 106948 doi: 10.1016/j.phrs.2023.106948
11
Satyam K. Ghodasara, Kristine M. Hauser, Kaitlyn M. Oldewurtel, Rolando H. Rolandelli, Zoltan H. Nemeth. A Comparison of Clinical Outcomes of Colectomies for Pediatric and Adult Patients With Inflammatory Bowel DiseaseThe American Surgeon™ 2024; 90(11): 2921 doi: 10.1177/00031348241256066
12
Daniel Schweckendiek, Gerhard Rogler. Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block?Digestion 2024; 105(6): 411 doi: 10.1159/000540421
13
Recent advances in the therapeutics and modes of action of a range of agents used to treat ulcerative colitis and related inflammatory conditionsInflammopharmacology 2025;  doi: 10.1007/s10787-025-01906-8
14
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovationsWorld Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
15
Mohamed Mahmoud Hafez, Ibrahim Halil Bahcecioglu, Mehmet Yalniz, Karim Abdelwahab Kouta, Ahmed Tawheed. Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelinesWorld Journal of Methodology 2025; 15(4): 107643 doi: 10.5662/wjm.v15.i4.107643
16
Victor O Adedara, Charles A Adedara, Nicola D Ruth, Grant U Alozie, Nate Nettagul. Advancements in the Management of Pediatric and Adult Inflammatory Bowel Disease: A Systematic Review of Treatment Strategies and Long-Term OutcomesCureus 2024;  doi: 10.7759/cureus.72324
17
Bailu Geng, Congmin Zhu, Zilu Cui, Yiqian Chen, Qian Zhang, Haiyun Shi, Li Min, Shengtao Zhu, Weizhen Zhang, Mengran Zhao, Shutian Zhang, Junxuan Xu. Maslinic acid alleviates ulcerative colitis by inhibiting the colitis-aggravating pathogen Clostridium perfringens and modulating gut microbiotaPhytomedicine 2025; 146: 157144 doi: 10.1016/j.phymed.2025.157144
18
Laura Arosa, Miguel Camba-Gómez, Olga Golubnitschaja, Javier Conde-Aranda. Predictive, preventive and personalised approach as a conceptual and technological innovation in primary and secondary care of inflammatory bowel disease benefiting affected individuals and populationsEPMA Journal 2024; 15(1): 111 doi: 10.1007/s13167-024-00351-x
19
Ali Alipouriani, Kamil Erozkan, Lukas Schabl, Himani Sancheti, Shaji Sebastian, Serre-Yu Wong, Phil Tozer, Benjamin L Cohen, Stefan D Holubar. TOpClass Class 4 Perineal Crohn’s Disease: A Systematic Review and Meta-analysis of Perineal Wound Complication After Proctectomy in Crohn’s PatientsInflammatory Bowel Diseases 2025; 31(4): 1150 doi: 10.1093/ibd/izae198